Comparison of radiation shielding requirements for HDR brachytherapy using 169Yb and 192Ir sources.
169Yb has received a renewed focus lately as an alternative to 192Ir sources for high dose rate (HDR) brachytherapy. Following the results of a recent work by our group which proved 169Yb to be a good candidate for HDR prostate brachytherapy, this work seeks to quantify the radiation shielding requirements for 169Yb HDR brachytherapy applications in comparison to the corresponding requirements for the current 192Ir HDR brachytherapy standard. Monte Carlo simulation (MC) is used to obtain 169Yb and 192Ir broad beam transmission data through lead and concrete. Results are fitted to an analytical equation which can be used to readily calculate the barrier thickness required to achieve a given dose rate reduction. Shielding requirements for a HDR brachytherapy treatment room facility are presented as a function of distance, occupancy, dose limit, and facility workload, using analytical calculations for both 169Yb and 192Ir HDR sources. The barrier thickness required for 169Yb is lower than that for 192Ir by a factor of 4-5 for lead and 1.5-2 for concrete. Regarding 169Yb HDR brachytherapy applications, the lead shielding requirements do not exceed 15 mm, even in highly conservative case scenarios. This allows for the construction of a lead door in most cases, thus avoiding the construction of a space consuming, specially designed maze. The effects of source structure, attenuation by the patient, and scatter conditions within an actual treatment room on the above-noted findings are also discussed using corresponding MC simulation results.
Lymperopoulou
G
G
Nuclear and Particle Physics Section, Physics Department, University of Athens, Panepistimioupolis, Ilisia, 157 71, Athens, Greece. glymper@phys.uoa.gr
Papagiannis
P
P
Sakelliou
L
L
Georgiou
E
E
Hourdakis
C J
CJ
Baltas
D
D
D001918:Brachytherapy / Q000379:methods*; D003198:Computer Simulation; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use*; D007854:Lead; D009010:Monte Carlo Method; D011834:Radiation Monitoring; D011835:Radiation Protection / Q000379:methods* / Q000592:standards*; D011868:Radioisotopes / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012542:Scattering, Radiation; D012984:Software; D015018:Ytterbium / Q000627:therapeutic use*
D007496:Iridium Radioisotopes; D011868:Radioisotopes; D007854:Lead; D015018:Ytterbium